Strand Therapeutics is an early-stage biotechnology company utilizing synthetic biology to genetically program mRNA. They are developing the first platform for creating programmable, long-acting mRNA therapeutics to deliver precise, multi-functional, and potentially curative therapies for patients.
- Category
- Programmable mRNA Therapeutics
- Stage
- Series B
- Employees
- 200
- HQ
- Boston, United States
- Founded
- 2017
- Funding
- $256M